[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fngd3jcYJxt4hNsyC_WIWU2yYYwhWKIs7nLPNoL8TZjs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":48,"rows":55},"University of Rome Tor Vergata",[4],90,false,12,8,329069,3,69,[14,17,19,21,23,25,28,30],{"name":15,"count":16},"Colon Cancer",4,{"name":18,"count":16},"Surgery",{"name":20,"count":16},"Heart Failure",{"name":22,"count":11},"Morbid Obesity",{"name":24,"count":11},"Breast Cancer",{"name":26,"count":27},"Prostate Cancer",2,{"name":29,"count":27},"Metabolic Syndrome",{"name":31,"count":27},"Rectal Cancer",[33,38,43],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06130046","MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation","2026-05-01","MR-proADM dosage",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT07286461","VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol","2027-09-30","letermovir prophylaxis",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07067749","Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer","2028-08-15","Circulating tumour DNA levels assessment",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,85,108,132,161,188,206,233,258,276,301,328,346,370,395,420,438,463,489,515,538,564,589,615,641,673,691,709,727],{"intervention":47,"totalTrials":57,"cells":58},1,{"EARLY_PHASE1":59,"PHASE1":62,"PHASE2":64,"PHASE3":66,"PHASE4":81,"NA":83},{"trials":60,"activeCount":61},[],0,{"trials":63,"activeCount":61},[],{"trials":65,"activeCount":61},[],{"trials":67,"activeCount":57,"soonestReadout":46},[68],{"nctId":44,"briefTitle":45,"status":69,"phases":70,"primaryCompletion":46,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":80},"RECRUITING",[52],"2030-08-15","2025-08-15",92,[75,76,77,78,79],"Bladder (Urothelial, Transitional Cell) Cancer","Bladder Cancer Requiring Cystectomy","Bladder Carcinoma","Bladder Neoplasm","Muscle Invasive Bladder Cancer (MIBC)",[47],{"trials":82,"activeCount":61},[],{"trials":84,"activeCount":61},[],{"intervention":37,"totalTrials":57,"cells":86},{"EARLY_PHASE1":87,"PHASE1":89,"PHASE2":91,"PHASE3":93,"PHASE4":95,"NA":97},{"trials":88,"activeCount":61},[],{"trials":90,"activeCount":61},[],{"trials":92,"activeCount":61},[],{"trials":94,"activeCount":61},[],{"trials":96,"activeCount":61},[],{"trials":98,"activeCount":57,"soonestReadout":36},[99],{"nctId":34,"briefTitle":35,"status":69,"phases":100,"primaryCompletion":36,"completion":101,"start":102,"enrollment":103,"conditions":104,"interventions":107},[],"2026-12-01","2022-12-01",300,[105,106],"Kidney Transplant; Complications","Liver Transplant; Complications",[37],{"intervention":42,"totalTrials":57,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":116,"PHASE4":118,"NA":120},{"trials":111,"activeCount":61},[],{"trials":113,"activeCount":61},[],{"trials":115,"activeCount":61},[],{"trials":117,"activeCount":61},[],{"trials":119,"activeCount":61},[],{"trials":121,"activeCount":57,"soonestReadout":41},[122],{"nctId":39,"briefTitle":40,"status":123,"phases":124,"primaryCompletion":41,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":131},"NOT_YET_RECRUITING",[],"2027-12-30","2025-12-15",290,[129,130],"Allogeneic Hematopoietic Stem Cell Transplantation Recipient","CMV",[42],{"intervention":133,"totalTrials":57,"cells":134},"Pioglitazone",{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":157,"NA":159},{"trials":136,"activeCount":61},[],{"trials":138,"activeCount":61},[],{"trials":140,"activeCount":61},[],{"trials":142,"activeCount":61},[143],{"nctId":144,"briefTitle":145,"status":146,"phases":147,"primaryCompletion":148,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":156},"NCT00376870","PIoglitazone for PrEvention of Restenosis in Diabetic Patients","UNKNOWN",[52],"2010-12","2011-04","2008-07",160,[153,154,155],"Coronary Atherosclerosis","Coronary Restenosis","Diabetes",[133],{"trials":158,"activeCount":61},[],{"trials":160,"activeCount":61},[],{"intervention":162,"totalTrials":57,"cells":163},"bacillus Calmette-Guerin",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":184,"NA":186},{"trials":165,"activeCount":61},[],{"trials":167,"activeCount":61},[],{"trials":169,"activeCount":61},[],{"trials":171,"activeCount":61},[172],{"nctId":173,"briefTitle":174,"status":175,"phases":176,"primaryCompletion":177,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT01442519","Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer","COMPLETED",[52],"2002-06","1994-01",212,[181],"Bladder Cancer",[162,183],"electromotive mitomycin",{"trials":185,"activeCount":61},[],{"trials":187,"activeCount":61},[],{"intervention":183,"totalTrials":57,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":202,"NA":204},{"trials":191,"activeCount":61},[],{"trials":193,"activeCount":61},[],{"trials":195,"activeCount":61},[],{"trials":197,"activeCount":61},[198],{"nctId":173,"briefTitle":174,"status":175,"phases":199,"primaryCompletion":177,"completion":177,"start":178,"enrollment":179,"conditions":200,"interventions":201},[52],[181],[162,183],{"trials":203,"activeCount":61},[],{"trials":205,"activeCount":61},[],{"intervention":207,"totalTrials":57,"cells":208},"intravesical passive diffusion mitomycin",{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":229,"NA":231},{"trials":210,"activeCount":61},[],{"trials":212,"activeCount":61},[],{"trials":214,"activeCount":61},[],{"trials":216,"activeCount":61},[217],{"nctId":218,"briefTitle":219,"status":175,"phases":220,"primaryCompletion":221,"completion":222,"start":178,"enrollment":223,"conditions":224,"interventions":228},"NCT01920269","Intravesical Adjuvant Electromotive Mitomycin-C",[51,52],"2004-12","2013-06",331,[225,226,227],"Bladder Cancer TNM Staging Primary Tumor (T) Ta","Bladder Cancer TNM Staging Primary Tumor (T) T1","Bladder Cancer Transitional Cell Grade",[207],{"trials":230,"activeCount":61},[],{"trials":232,"activeCount":61},[],{"intervention":234,"totalTrials":57,"cells":235},"liposomal lactoferrin",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":254,"NA":256},{"trials":237,"activeCount":61},[],{"trials":239,"activeCount":61},[],{"trials":241,"activeCount":61},[],{"trials":243,"activeCount":61},[244],{"nctId":245,"briefTitle":246,"status":175,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":73,"conditions":250,"interventions":252},"NCT04475120","Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients",[51,52],"2020-07-02","2020-04-15",[251],"Covid19",[234,253],"SOC therapy",{"trials":255,"activeCount":61},[],{"trials":257,"activeCount":61},[],{"intervention":253,"totalTrials":57,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":272,"NA":274},{"trials":261,"activeCount":61},[],{"trials":263,"activeCount":61},[],{"trials":265,"activeCount":61},[],{"trials":267,"activeCount":61},[268],{"nctId":245,"briefTitle":246,"status":175,"phases":269,"primaryCompletion":248,"completion":248,"start":249,"enrollment":73,"conditions":270,"interventions":271},[51,52],[251],[234,253],{"trials":273,"activeCount":61},[],{"trials":275,"activeCount":61},[],{"intervention":277,"totalTrials":57,"cells":278},"Mitomycin-C 40 mg",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":297,"NA":299},{"trials":280,"activeCount":61},[],{"trials":282,"activeCount":61},[],{"trials":284,"activeCount":61},[],{"trials":286,"activeCount":61},[287],{"nctId":288,"briefTitle":289,"status":175,"phases":290,"primaryCompletion":291,"completion":292,"start":178,"enrollment":293,"conditions":294,"interventions":296},"NCT01149174","Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer",[52],"2003-12","2009-06",352,[295],"Superficial Bladder Cancer",[277],{"trials":298,"activeCount":61},[],{"trials":300,"activeCount":61},[],{"intervention":302,"totalTrials":57,"cells":303},"Simvastatin",{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":324,"NA":326},{"trials":305,"activeCount":61},[],{"trials":307,"activeCount":61},[],{"trials":309,"activeCount":61},[],{"trials":311,"activeCount":61},[312],{"nctId":313,"briefTitle":314,"status":175,"phases":315,"primaryCompletion":316,"completion":148,"start":317,"enrollment":318,"conditions":319,"interventions":322},"NCT00854503","Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients",[52],"2010-03","2008-09",30,[320,321],"Type 2 Diabetes","Diabetic Dyslipidemia",[302,323],"Rosuvastatin",{"trials":325,"activeCount":61},[],{"trials":327,"activeCount":61},[],{"intervention":323,"totalTrials":57,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":342,"NA":344},{"trials":331,"activeCount":61},[],{"trials":333,"activeCount":61},[],{"trials":335,"activeCount":61},[],{"trials":337,"activeCount":61},[338],{"nctId":313,"briefTitle":314,"status":175,"phases":339,"primaryCompletion":316,"completion":148,"start":317,"enrollment":318,"conditions":340,"interventions":341},[52],[320,321],[302,323],{"trials":343,"activeCount":61},[],{"trials":345,"activeCount":61},[],{"intervention":347,"totalTrials":57,"cells":348},"Hesperidin",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":364,"PHASE4":366,"NA":368},{"trials":350,"activeCount":61},[],{"trials":352,"activeCount":61},[],{"trials":354,"activeCount":61},[355],{"nctId":356,"briefTitle":357,"status":146,"phases":358,"primaryCompletion":359,"completion":148,"start":360,"enrollment":318,"conditions":361,"interventions":363},"NCT00914251","Vascular Effects of Hesperidin in Metabolic Syndrome",[51],"2009-03","2008-11",[362,29],"Endothelial Dysfunction",[347],{"trials":365,"activeCount":61},[],{"trials":367,"activeCount":61},[],{"trials":369,"activeCount":61},[],{"intervention":371,"totalTrials":57,"cells":372},"intravesical electromotive administration of mitomycin",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":389,"PHASE4":391,"NA":393},{"trials":374,"activeCount":61},[],{"trials":376,"activeCount":61},[],{"trials":378,"activeCount":61},[379],{"nctId":380,"briefTitle":381,"status":175,"phases":382,"primaryCompletion":383,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":388},"NCT04311580","Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure",[51],"2013-12-31","2020-03-10","2000-01-01",52,[181],[371],{"trials":390,"activeCount":61},[],{"trials":392,"activeCount":61},[],{"trials":394,"activeCount":61},[],{"intervention":396,"totalTrials":57,"cells":397},"Hyaluronic Acid",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":399,"activeCount":61},[],{"trials":401,"activeCount":61},[],{"trials":403,"activeCount":61},[404],{"nctId":405,"briefTitle":406,"status":175,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":318,"conditions":410,"interventions":412},"NCT02207608","Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects",[51],"2012-08","2011-09",[411],"Poisoning by BCG Vaccine",[396,413],"BCG",{"trials":415,"activeCount":61},[],{"trials":417,"activeCount":61},[],{"trials":419,"activeCount":61},[],{"intervention":413,"totalTrials":57,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":423,"activeCount":61},[],{"trials":425,"activeCount":61},[],{"trials":427,"activeCount":61},[428],{"nctId":405,"briefTitle":406,"status":175,"phases":429,"primaryCompletion":408,"completion":408,"start":409,"enrollment":318,"conditions":430,"interventions":431},[51],[411],[396,413],{"trials":433,"activeCount":61},[],{"trials":435,"activeCount":61},[],{"trials":437,"activeCount":61},[],{"intervention":439,"totalTrials":57,"cells":440},"Postoperative antibiotico-prophylaxis",{"EARLY_PHASE1":441,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":461},{"trials":442,"activeCount":61},[443],{"nctId":444,"briefTitle":445,"status":175,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT04977882","Abdominal Drainage, Postoperative Antibiotico-prophylaxis and CME With D3 Lyphadenectomy Effect on Gastrointestinal Function in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis for Right Colon Cancer",[49],"2022-08-01","2023-08-01","2020-10-01",36,[15],[439],{"trials":454,"activeCount":61},[],{"trials":456,"activeCount":61},[],{"trials":458,"activeCount":61},[],{"trials":460,"activeCount":61},[],{"trials":462,"activeCount":61},[],{"intervention":464,"totalTrials":57,"cells":465},"Bronchodilators",{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":467,"activeCount":61},[],{"trials":469,"activeCount":61},[],{"trials":471,"activeCount":61},[],{"trials":473,"activeCount":61},[],{"trials":475,"activeCount":61},[],{"trials":477,"activeCount":61},[478],{"nctId":479,"briefTitle":480,"status":146,"phases":481,"primaryCompletion":482,"start":483,"enrollment":484,"conditions":485,"interventions":488},"NCT02008162","Bronchoreversibility and Radiologic Morphology of Emphysema",[],"2013-12","2009-11",60,[486,487],"Emphysema","COPD",[464],{"intervention":490,"totalTrials":57,"cells":491},"Local Paclitaxel",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":493,"activeCount":61},[],{"trials":495,"activeCount":61},[],{"trials":497,"activeCount":61},[],{"trials":499,"activeCount":61},[],{"trials":501,"activeCount":61},[],{"trials":503,"activeCount":61},[504],{"nctId":505,"briefTitle":506,"status":175,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":514},"NCT02625740","Ultrasound to Enhance Paclitaxel Uptake in Critical Limb Ischemia: the PACUS Trial",[54],"2014-11","2015-11","2013-11",56,[513],"Peripheral Arterial Disease, Angioplasty",[490],{"intervention":516,"totalTrials":57,"cells":517},"GLP-1",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":519,"activeCount":61},[],{"trials":521,"activeCount":61},[],{"trials":523,"activeCount":61},[],{"trials":525,"activeCount":61},[],{"trials":527,"activeCount":61},[],{"trials":529,"activeCount":61},[530],{"nctId":531,"briefTitle":532,"status":175,"phases":533,"primaryCompletion":534,"completion":534,"start":360,"enrollment":535,"conditions":536,"interventions":537},"NCT00856700","Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome",[54],"2012-06",20,[29],[516],{"intervention":539,"totalTrials":57,"cells":540},"Immunosuppressive",{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":549,"NA":551},{"trials":542,"activeCount":61},[],{"trials":544,"activeCount":61},[],{"trials":546,"activeCount":61},[],{"trials":548,"activeCount":61},[],{"trials":550,"activeCount":61},[],{"trials":552,"activeCount":61},[553],{"nctId":554,"briefTitle":555,"status":175,"phases":556,"primaryCompletion":557,"completion":558,"start":559,"enrollment":73,"conditions":560,"interventions":563},"NCT05808192","De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal",[],"2022-02-01","2022-05-01","2020-09-01",[561,562],"Single Transplant","5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS",[539],{"intervention":565,"totalTrials":57,"cells":566},"fluorouracil\u002Firinotecan\u002Flevo-folinic acid\u002Fbevacizumab",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":568,"activeCount":61},[],{"trials":570,"activeCount":61},[],{"trials":572,"activeCount":61},[],{"trials":574,"activeCount":61},[],{"trials":576,"activeCount":61},[],{"trials":578,"activeCount":61},[579],{"nctId":580,"briefTitle":581,"status":175,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT01533740","Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients",[],"2014-02","2012-03",31,[587],"Metastatic Colorectal Cancer",[565],{"intervention":590,"totalTrials":57,"cells":591},"tixagevimab-cilgavimab",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":593,"activeCount":61},[],{"trials":595,"activeCount":61},[],{"trials":597,"activeCount":61},[],{"trials":599,"activeCount":61},[],{"trials":601,"activeCount":61},[],{"trials":603,"activeCount":61},[604],{"nctId":605,"briefTitle":606,"status":175,"phases":607,"primaryCompletion":608,"completion":609,"start":557,"enrollment":610,"conditions":611,"interventions":614},"NCT05629923","EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS",[],"2022-11-01","2022-11-30",306,[612,613],"COVID-19 Pandemic","Transplant-Related Disorder",[590],{"intervention":616,"totalTrials":57,"cells":617},"Gilteritinib",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":628},{"trials":619,"activeCount":61},[],{"trials":621,"activeCount":61},[],{"trials":623,"activeCount":61},[],{"trials":625,"activeCount":61},[],{"trials":627,"activeCount":61},[],{"trials":629,"activeCount":61},[630],{"nctId":631,"briefTitle":632,"status":146,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},"NCT05791890","GilteRInf 2022 Study (Gilteritinib Related Infections)",[],"2024-05-31","2024-12-31","2022-05-31",78,[639],"Acute Myeloid Leukemia",[616],{"intervention":642,"totalTrials":57,"cells":643},"Terbinafine Topical Gel",{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":652,"NA":654},{"trials":645,"activeCount":61},[],{"trials":647,"activeCount":61},[],{"trials":649,"activeCount":61},[],{"trials":651,"activeCount":61},[],{"trials":653,"activeCount":61},[],{"trials":655,"activeCount":61},[656],{"nctId":657,"briefTitle":658,"status":146,"phases":659,"primaryCompletion":660,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":668},"NCT05482763","Mycosis Culture Collection From Dermatological Isolated",[],"2025-07-20","2025-12-25","2022-07-20",200,[665,666,667],"Onychomycosis","Resistant Infection","Nail Diseases",[642,669,670,671,672],"Itraconazole 200 mg","Terbinafine 250 mg","Ciclopirox Topical Gel","Amorolfine 50 MG\u002FML",{"intervention":669,"totalTrials":57,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":676,"activeCount":61},[],{"trials":678,"activeCount":61},[],{"trials":680,"activeCount":61},[],{"trials":682,"activeCount":61},[],{"trials":684,"activeCount":61},[],{"trials":686,"activeCount":61},[687],{"nctId":657,"briefTitle":658,"status":146,"phases":688,"primaryCompletion":660,"completion":661,"start":662,"enrollment":663,"conditions":689,"interventions":690},[],[665,666,667],[642,669,670,671,672],{"intervention":670,"totalTrials":57,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":694,"activeCount":61},[],{"trials":696,"activeCount":61},[],{"trials":698,"activeCount":61},[],{"trials":700,"activeCount":61},[],{"trials":702,"activeCount":61},[],{"trials":704,"activeCount":61},[705],{"nctId":657,"briefTitle":658,"status":146,"phases":706,"primaryCompletion":660,"completion":661,"start":662,"enrollment":663,"conditions":707,"interventions":708},[],[665,666,667],[642,669,670,671,672],{"intervention":671,"totalTrials":57,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":721},{"trials":712,"activeCount":61},[],{"trials":714,"activeCount":61},[],{"trials":716,"activeCount":61},[],{"trials":718,"activeCount":61},[],{"trials":720,"activeCount":61},[],{"trials":722,"activeCount":61},[723],{"nctId":657,"briefTitle":658,"status":146,"phases":724,"primaryCompletion":660,"completion":661,"start":662,"enrollment":663,"conditions":725,"interventions":726},[],[665,666,667],[642,669,670,671,672],{"intervention":672,"totalTrials":57,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":730,"activeCount":61},[],{"trials":732,"activeCount":61},[],{"trials":734,"activeCount":61},[],{"trials":736,"activeCount":61},[],{"trials":738,"activeCount":61},[],{"trials":740,"activeCount":61},[741],{"nctId":657,"briefTitle":658,"status":146,"phases":742,"primaryCompletion":660,"completion":661,"start":662,"enrollment":663,"conditions":743,"interventions":744},[],[665,666,667],[642,669,670,671,672]]